{
  "ticker": "LLY",
  "target_date": "2025-09-26",
  "actual_date": "2025-09-26",
  "collected_at": "2025-12-08T12:19:56.189410",
  "price": {
    "open": 723.06,
    "high": 727.93,
    "low": 716.03,
    "close": 723.4774780273438,
    "volume": 3559700,
    "change_1d_pct": 1.39,
    "change_7d_pct": -4.68,
    "change_30d_pct": 6.09
  },
  "technicals": {
    "rsi_14": 43.81,
    "sma_20": 744.01,
    "sma_50": 733.42,
    "macd": 1.468,
    "macd_signal": 5.257,
    "macd_histogram": -3.79,
    "bb_upper": 771.03,
    "bb_lower": 717.0,
    "price_vs_sma20_pct": -2.76,
    "price_vs_sma50_pct": -1.36,
    "volume_ratio": 1.08
  },
  "fundamentals": {
    "market_cap": 892507848704,
    "pe_ratio": 48.779762,
    "forward_pe": 43.93623,
    "price_to_book": 37.484753,
    "price_to_sales": 15.020378,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.47,
    "pct_from_52w_low": 59.61
  },
  "macro": {
    "spy": {
      "price": 661.82,
      "change_1d_pct": 0.57,
      "change_7d_pct": 0.21
    },
    "vix": {
      "level": 15.29,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.19
    },
    "dollar_index": {
      "level": 98.15
    },
    "gold": {
      "price": 3775.3
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "GLP-1 race evolves as Amgen & weight-loss pills enter the scene",
      "source": "Yahoo",
      "datetime": 1758922200,
      "summary": "Amgen (AMGN) is eyeing the obesity drug race, currently dominated by Eli Lilly (LLY) and Novo Nordisk (NVO), with its two late-stage weight-loss drug trials. Citi Research managing director Geoff Meacham joins Market Domination host Josh Lipton to discuss the weight-loss drug market, the advent of p",
      "url": "https://finnhub.io/api/news?id=147905f9e2f8d9968b427debee726b12673a995cdda829ea48380e5da823d035"
    },
    {
      "headline": "EU Approves Lilly's Kisunla for Early Alzheimer's",
      "source": "Yahoo",
      "datetime": 1758920501,
      "summary": "Drug shown to slow memory and functional decline in trials",
      "url": "https://finnhub.io/api/news?id=4e58ae7b625ac7688675ca082aa63f190114d5490ec7ac7ca8c2706f193c0077"
    },
    {
      "headline": "Heard on the Street Recap: Another Dose of Tariffs",
      "source": "Yahoo",
      "datetime": 1758919768,
      "summary": "President Trump unveiled 100% tariffs on pharmaceuticals.  The tariffs, however, only apply to patented or branded drugs and those made by companies that aren't building plants in the U.S. Shares of pharma giants such as Eli Lilly, AstraZeneca, and GSK actually rose slightly.  Luxury furniture selle",
      "url": "https://finnhub.io/api/news?id=a90311413121e17b29e41f244656c28d6cdfc916f0a113b690f19d3dbb8b7a33"
    },
    {
      "headline": "All bark, no bite: Trump\u2019s latest trade war turns into another TACO salad for Wall Street",
      "source": "Yahoo",
      "datetime": 1758919246,
      "summary": "Markets actually improved on the latest surprise round of Trump tariffs.",
      "url": "https://finnhub.io/api/news?id=7cf425f76024ac3ab32825f274a47768aea690dc95adb032973a9f613783d98e"
    },
    {
      "headline": "Stocks Close Higher After Trump Unveils New Tariffs",
      "source": "Yahoo",
      "datetime": 1758918660,
      "summary": "U.S. stocks ended higher Friday after a three-day losing streak, showing investors aren\u2019t concerned about the broad impact of new tariffs on drugs, trucks and furniture.",
      "url": "https://finnhub.io/api/news?id=2e7103a4b46ce12e8363a0817076daf0d2e8a329f7bbfc6c7af0a58bdf05dbea"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-09-22",
      "description": "xslF345X05/form4-09222025_040901.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000009/xslF345X05/form4-09222025_040901.xml"
    },
    {
      "form": "4",
      "date": "2025-09-19",
      "description": "xslF345X05/form4-09192025_040901.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000007/xslF345X05/form4-09192025_040901.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142191.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000126238825000004/xslF345X05/wk-form4_1758142191.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142140.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000242/xslF345X05/wk-form4_1758142140.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142082.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000134082325000006/xslF345X05/wk-form4_1758142082.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}